STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: A randomized multicenter clinical trial

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 2, 2002, Pages 131-136

  Vail, David M ^a,b   Kurzman, Ilene D ^a,b   Glawe, Phyllis C ^b,c   O'Brien, Maura G ^b,d   Chun, Ruthanne ^b,e   Garrett, Laura D ^b,e   Obradovich, Joyce E ^b,f   Fred, Rogers M ^b,g   Khanna, Chand ^b,h   Colbern, Gail T ^b,i   Working, Peter K ^b,i  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Sonora Veterinary Specialists   (United States)

^d Veterinary Centers of America   (United States)

^e KANSAS STATE UNIVERSITY   (United States)

^f Oakland Veterinary Referral Services   (United States)

^g Red Bank Veterinary Referral Center   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ ALZA CORPORATION   (United States)

Author keywords

Canine; Carboplatin; Cisplatin; Osteosarcoma; Stealth liposome

Indexed keywords

CARBOPLATIN; CISPLATIN; LIPOSOME; MITOPODOZIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DOG DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; LIMB AMPUTATION; MALE; MULTICENTER STUDY; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RANDOMIZATION; SURVIVAL TIME; TREATMENT OUTCOME;

AMPUTATION; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; DRUG COMPOUNDING; FEMALE; FOLLOW-UP STUDIES; LIFE TABLES; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; OSTEOSARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036351312     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0469-8     Document Type: Article

References (28)

1. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models
2. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 Cases (1987-1990)
3. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 Cases (1991 to 1993)
4. Canine osteosarcoma: A clinicopathologic study of 194 cases
5. Tumors of the skeletal system
6. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
7. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 Cases (1990-1996)
8. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma
9. Toxicity of platinum-based anticancer drugs
10. Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome-encapsulated muramyl tirpeptide and cisplatin
11. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide
12. Sarcomas of bone
13. A phase I and pharmacology study of an oral platinum complex, JM216: Dose dependent pharmacokinetics with single-dose administration
14. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077), in tumor-bearing mice
15. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin
16. Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors
17. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
18. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and 8 schedule
19. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 Cases (1978-1988)
20. Liposomes as a drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor resistance in vivo, induction of drug resistance, nephrotoxicity and Pt distribution
21. Amputation and cisplatin for treatment of canine osteosarcoma
22. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats
23. Spontaneously occurring tumors of companion animals as models for human cancer
24. Biological properties of sterically stabilized liposomes
25. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys
26. Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy
27. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue
28. Disposition of platinum (Pt) in B16 murine melanoma tumors after administration of cisplatin or pegylated liposomal-cisplatin formulations (SPI-077 and SPI-077 B103)